News
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-News: BB BIOTECH AG: Etablierte Kernbeteiligungen ermöglichen einen erhöhten Investitionsgrad
Ordentliche Generalversammlung - Aktionäre nehmen alle Anträge des Verwaltungsrats an
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis
Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Medicines Agency’s (EMA) CHMP has recommended
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026006150/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma announces changes to its Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced changes to its Executive Committee as current members Lee Heeson, President International, and
VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing
GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID
GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
Regulatory News:
Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005635/en/
Vifor Pharma and Cara Therapeutics (Nasdaq:CARA)
Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1
Regulatory News:
Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient
Vifor Pharma erzielt im 1. Halbjahr 2021 starkes Wachstum und bestätigt Jahresprognose1
Regulatory News:
Die Vifor Pharma Gruppe erzielte im 1. Halbjahr 2021 ein profitables Umsatzwachstum dank einer starken Erholung von Ferinject®/Injectafer® mit einem Umsatzplus von 22.8% zu kWk
Abbas Hussain Appointed as New Chief Executive Officer of Vifor Pharma
Regulatory News:
Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain
Abbas Hussain zum neuen Chief Executive Officer von Vifor Pharma ernannt
Regulatory News:
Abbas Hussain (56, britischer Staatsbürger) verfügt über eine mehr als 30-jährige erfolgreiche und internationale Karriere als Führungskraft im Gesundheitssektor. Von 2008 bis
Vifor Pharma to revise DIAMOND study, readout expected in H2 2021
Regulatory News:
Vifor Pharma Group today announced that the phase-IIIb DIAMOND study has been amended with new and clinically relevant endpoints, including a new primary endpoint of efficacy in
93rd Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 93rd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the ongoing COVID-19
93. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der 93. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Beschlussanträge des Verwaltungsrats genehmigt. Angesichts der anhaltenden
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21)
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005652/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma to propose Åsa Riisberg for appointment to Board of Directors
Regulatory News:
Vifor Pharma is pleased to announce that the Board of Directors will propose Åsa Riisberg for election to the Board at the Annual General Meeting on 6 May 2021.
Åsa Riisberg, a